264 In the index

NMN NMN

A vitamin B3-related supplement studied in early human trials for boosting a molecule tied to cellular energy and aging. Some trials in postmenopausal women showed improved insulin response and muscle function, while others found no real benefit, leaving the human evidence mixed.

Also known as Beta-NMN, nicotinamide mononucleotide, Nicotinamide ribotide, 2KG6QX4W0V, Alpha9, ELITEHEALTH, REUS NR, RefChem:854107, Mononucleotide, Nicotinamide

Effects Longevity

Routes Oral

Legal status Dietary supplement

WADA Not listed

3D Molecular Structure of C₁₁H₁₅N₂O₈P

Drag to rotate · scroll to zoom

Chemistry

Formula: C11H15N2O8P
Molar mass: 334.22
CAS: 1094-61-7
PubChem CID: 14180
IUPAC name: [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
InChIKey: DAYLJWODMCOQEW-TURQNECASA-N

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 250-500 mg/day

Reported range 125-1000 mg/day

Route Oral

Frequency Once daily

Duration Ongoing (supplement use)

Sold as a dietary supplement marketed for NAD+ support and longevity; human trial evidence for meaningful clinical benefit is still early-stage.

Where this comes from Early-phase clinical trials; supplement-industry dosing

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.